# Tempest Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2014

- Company: [Tempest Therapeutics, Inc.](/companies/tpst.md) (CIK 1544227)
- Form: 10-Q
- Filed: 2014-08-07
- Accepted by EDGAR: Aug 7, 2014, 09:05 ET
- Period: 2014-06-30
- Accession: 0001104659-14-057930
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1544227/000110465914057930/a14-14048_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1544227/000110465914057930/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2014-04-01 to 2014-06-30 | $4.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2014-01-01 to 2014-06-30 | $9.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2014-04-01 to 2014-06-30 | $5.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2014-01-01 to 2014-06-30 | $8.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2014-04-01 to 2014-06-30 | −$9.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2014-01-01 to 2014-06-30 | −$17.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2014-04-01 to 2014-06-30 | −$9.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2014-01-01 to 2014-06-30 | −$17.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-04-01 to 2014-06-30 | −$0.42 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2014-01-01 to 2014-06-30 | −$0.83 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 6 months, 2014-01-01 to 2014-06-30 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-06-30 | $16.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-06-30 | $82.6m | us-gaap:AssetsCurrent |
| Total assets | at 2014-06-30 | $85.8m | us-gaap:Assets |
| Current liabilities | at 2014-06-30 | $7.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-06-30 | $7.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2014-06-30 | $78.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 29,533 characters.

*This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Without limiting the foregoing, the words “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “target,” “goal”, “seek”, “likely” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us up to, and including, the date of this document, and we expressly disclaim any obligation to update any such forward-looking statements to reflect events or circumstances that arise after the date hereof. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain important factors, including those set forth in this Item 2 — “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013, and elsewhere in this Quarterly Report on Form 10-Q. You should carefully review those factors and also carefully review the risks outlined in other documents that we file from time to time with the Securities and Exchange Commission, or SEC.*

### Overview

OvaScience is a global life science company focused on the discovery, development, and commercialization of new fertility treatments. Our patented technology is based on egg precursor cells, or EggPCs, which are found in the outer layer of a woman’s own ovaries. The discovery of EggPCSM cells countered a long-held medical belief that women are born with a set number of eggs, thereby enabling new possibilities in the treatment of female infertility.

Our portfolio of fertility treatment options takes advantage of proprietary methods to identify and isolate EggPC cells from a patient’s ovarian tissue. By applying our EggPC technology platform in unique ways, we are developing and commercializing new fertility treatment options that are designed to improve egg quality and *in vitro* fertilization, or IVF.

We launched the AUGMENTSM treatment in 2014 in international regions through the AUGMENT Centers of Excellence, or ACE, access program. The treatment aims to improve egg quality and potentially increase the success of IVF by transferring mitochondria from a woman’s own EggPC cells into her mature egg during IVF.

Our treatment options under development include the following:

- The OvaPrimeSM treatment is designed to boost a woman’s egg reserve by transferring the EggPC cells from the outer layer of her ovary, or the outer cortex, back into the ovary for *in vivo* maturation during IVF. We are conducting additional proof-of-concept studies in 2014, and plan to introduce the OvaPrime treatment outside of the United States in 2015.
- The OvaTureSM treatment is a potential next-generation IVF option that seeks to mature a woman’s own EggPC cells outside the body into fertilizable eggs without the need for hormone hyperstimulation. We are conducting preclinical human proof-of-concept studies and expect to have results in 2014.

We believe our EggPC technology has the potential to make significant advances in the field of fertility because it may enable us to address poor egg and embryo quality due to age and other causes. We believe our EggPC technology could improve IVF by:

*Increasing live birth rates and reducing the number of IVF cycles.* By improving egg quality, we believe we may be able to increase the percentage of IVF treatments which result in live births and, in so doing, reduce the number of IVF cycles required.

*Reducing the incidence of multiple births.* By generating higher quality eggs, we believe our EggPC technology may allow for the transfer of fewer embryos per IVF cycle and, as a result, lower the incidence of multiple births and the associated complications for the mother and baby.

*Lowering the overall cost of IVF.* If we reduce the number of IVF cycles required for a live birth and the incidence of multiple births, we believe our fertility treatment options may also lower the overall costs associated with IVF.

*Reducing the need for hormonal hyperstimulation.* We are designing our OvaTure technology to mature EggPC cells into fertilizable eggs *in vitro*. OvaTure could reduce, or possibly eliminate, the need for hormonal hyperstimulation for the maturation of multiple oocytes prior to egg retrieval in the IVF process.

*Prevent inherited diseases.* OvaXonSM is a joint venture with Intrexon Corporation, which is focused on developing new applications to prevent the transmission of inherited diseases by gene editing EggPC cells for applications in human and animal health.

### AUGMENT

We launched the AUGMENT treatment in 2014 through our ACE access program in three international regions. We are more than halfway toward executing on our plan for at least 40 AUGMENT cycles in 2014. We expect to establish the ACE access program in other international regions, and to transition ACE clinics to commercial centers by year end 2014. We are targeting international regions that combine elements of the following key criteria:

- Key opinion leaders / high volume IVF clinics
- High quality IVF labs
- Out-of-pocket pay and high average cost per cycle
- Donor egg restrictions

As part of the AUGMENT treatment, a woman’s eggs may be revitalized by injecting mitochondria from her own EggPC cells into her egg during IVF. This has the potential to improve egg quality and thereby increase the success of IVF. With higher quality eggs, there is also the potential to reduce the need for multiple embryo transfers, which can result in a lower incidence of conceiving multiples (twins or triplets) and resulting complications.

The AUGMENT treatment complements the existing standard of practice for an IVF cycle. Prior to hormone hyperstimulation, a small tissue biopsy is taken from the outer layer of the ovary, where the EggPC cells reside. Our proprietary process identifies and isolates the patient’s own EggPC cells followed next by the removal of her own mitochondria within the EggPC cells. The patient’s own mitochondria are then injected into her egg at the time of intracytoplasmic sperm injection, or ICSI.

The development of assisted reproductive technologies has a long history of innovation based on techniques and tools developed outside the United States, including IVF and ICSI and, more recently, time-lapse imaging, oocyte vitrification and *in vitro* maturation of oocytes. We believe that this is a primary reason why the IVF market is predominantly located outside of the United States and why 90% of the 1.6 million annual IVF cycles are performed outside of the United States. Given the market size, as well as the innovative history and acceptance of new fertility methods and technologies internationally, we have consistently maintained a strategy to make our fertility treatments available to patients worldwide. We have commenced the international launch of the AUGMENT treatment through our ACE access program, and we are preparing to launch a second fertility treatment using this approach in 2015. We believe that we will be able to continue to offer the AUGMENT treatment in international regions where we have already launched the treatment and introduce the AUGMENT treatment into certain new international regions, in each case without pre-market review and approval, but if applicable regulatory bodies disagree, we may abandon the AUGMENT treatment in that region or suffer significant delay or expense in seeking necessary approvals. In September 2013, we received an “untitled” letter from the FDA advising us to file an Investigational New Drug, or IND, application for the AUGMENT treatment. We anticipate having further discussions with the FDA to present details on AUGMENT and to determine the appropriate path forward.

### Strategic Alliances

Strategic alliances are integral to our growth. These alliances provide access to breakthrough science, potential funding and innovative drug development programs, all intended to help us realize the full potential of our potential fertility treatment pipeline while at the same time allowing us to retain significant downstream value in our programs through commercialization rights.

### Collaboration with Intrexon to Accelerate Development of OvaTure

### Scope

In December 2013, we entered into a collaboration agreement, or the OvaTure Collaboration, with Intrexon governing the use of Intrexon’s synthetic biology technology platform for the accelerated development of our OvaTure platform. The OvaTure Collaboration provides that Intrexon will deliver laboratory and animal data to support the potential filing of an IND for the OvaTure treatment.

We own exclusive human commercial rights for the OvaTure treatment.

We participate as an equal member on the Joint Steering Committee, or JSC, and the Intellectual Property Committee, or IPC, in connection with the OvaTure Collaborations. The JSC shall agree upon the services and the activities to be included in the work plan, and the IPC has authority over intellectual property matters. We have the tie-breaking vote if there are any disputes within the JSC.

### Technology Access Fee Payable to Intrexon

The technology access fee we agreed to pay to Intrexon in connection with the OvaTure Collaboration is comprised of (1) the issuance of 273,224 shares or $2.5 million of our newly issued common stock that was already paid to Intrexon upon the execution of the OvaTure Collaboration in December 2013, and (2) a $2.5 million cash payment due in December 2014.

The technology access fee does not give us the right to any research and development services, and the technology access has no alternative future use to us. We therefore recorded $4.7 million in research and development expense in the year ended December 31, 2013 with $2.5 million recorded to additional paid-in capital and common stock and $2.2 million recorded in accrued liabilities, which represents the present value of the $2.5 million technology access fee due in December 2014.

The shares issued to Intrexon are subject to “piggy-back” registration rights that entitle Intrexon to have the shares included in any new registration statement filed in connection with an underwritten public offering, subject to underwriter cutback. The piggy-back registration rights will not be triggered by any offering subject to a registration statement filed prior to the execution of the OvaTure Collaboration, including our current universal shelf registration statement.

### Research and Development Funding and Potential Commercial Milestone

The JSC will also approve a budget under the work plan. We will reimburse Intrexon for research and development services performed, subject to budget caps. If applicable, we will also make a commercial milestone payment three months after the first commercial sale of OvaTure.

### Termination Rights

The OvaTure Collaboration has an indefinite term, and we have the right to terminate the collaboration after 90 days prior written notice, and either we or Intrexon may terminate the OvaTure Collaboration after a material breach by the other party that is not cured within 60 days. We may assign the OvaTure Collaboration in the event of a change of control transaction.

### Royalties

Upon the delivery of laboratory and animal data reasonably necessary to support the successful filing of an IND application, we will incur an obligation to pay Intrexon a mid-single digit royalty on net sales of any OvaTure fertility treatments, and the exact royalty will depend upon whether Intrexon completes the milestone by the targeted deadline of two years after technology transfer.

### Joint Venture

In December 2013, we also entered into a joint venture with Intrexon to leverage Intrexon’s synthetic biology technology platform and our technology relating to EggPC cells to create new applications to prevent inherited diseases for human and animal health. We and Intrexon formed OvaXon to conduct the joint venture. Each party contributed $1.5 million to OvaXon, each has a 50% equity interest, and research and development costs and profits will be split accordingly. Each party will also have 50% control over OvaXon and any disputes between us and Intrexon will be resolved through arbitration, if necessary.

We recorded our $1.5 million investment in OvaXon as an equity method investment in December 2013. During the three and six months ended June 30, 2014, we recorded $0.3 million and $0.4 million of losses, respectively, from our share of OvaXon’s losses during those periods.

### Critical Accounting Policies and Significant Judgments and Estimates

The discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We evaluate our estimates, on an ongoing basis, including those related to accrued expenses and assumptions in the valuation of stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances. Actual results could differ from those estimates.

Refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2013 for a discussion of our critical accounting policies and estimates.

There were no significant changes to our critical accounting policies and estimates in the six months ended June 30, 2014.

We have irrevocably elected not to follow the extended transition period available to emerging growth companies provided for in Securities Act Section 7(a)(2)(B) for complying with new or revised accounting standards.

### Results of Operations

The following table summarizes our results of operations for the three and six months ended June 30, 2014 and 2013, together with the change in these items in thousands of dollars and as a percentage:

|  | Three Months Ended, June 30, 2014 | 2013 | 2014 / 2013 Comparison Increase / (Decrease) $% |  | Six Months Ended, June 30, 2014 | 2013 | 2014 / 2013 Comparison Increase / (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $4,534 | $2,576 | $1,958 | 76% | $9,186 | $5,256 | $3,930 | 75% |
| Selling, general and administrative | 5,061 | 3,445 | 1,616 | 47% | 8,059 | 5,940 | 2,119 | 36% |
| Interest (expense) income, net | (27) | 25 | (52) | -208% | (84) | 43 | (127) | -295% |
| Other income (expense), net | 24 | — | 24 | 100% | 14 | — | 14 | 100% |
| Loss from equity method investment | (295) | — | (295) | 100% | (392) | — | (392) | 100% |
| Net Loss | $(9,893) | $(5,996) | $(3,897) | 65% | $(17,707) | $(11,153) | $(6,554) | 59% |

### Revenue

To date, we have not generated any revenue. Our ability to generate revenues will depend heavily on the successful development and eventual commercialization of AUGMENT, OvaPrime, OvaTure, and our other potential fertility treatments.

### Research and Development Expense

The $2.0 million or 76% increase in our research and development expense for the three months ended June 30, 2014 as compared to the three months ended June 30, 2013 was primarily attributable to:

- an increase of $1.0 million for employee compensation and related benefits, including stock-based compensation expense. The increase was primarily driven by the hiring of new research and development personnel;
- an increase of $0.7 million in research and development outside services and lab operations; and.
- an increase of $0.2 million in additional lab supplies, travel and facilities costs.

The $3.9 million or 75% increase in our research and development expense for the six months ended June 30, 2014 as compared to the six months ended June 30, 2013 was primarily attributable to:

- an increase of $1.0 million in license fees due to Massachusetts General Hospital related to a milestone triggered by our financing completed during the first quarter of 2014, of which $0.5 million was paid in April 2014, and the remaining $0.5 million will be paid in March 2015;
- an increase of $1.9 million for employee compensation and related benefits, including stock-based compensation expense. The increase was primarily driven by the hiring of new research and development personnel and stock-based compensation expense related to Founders’ shares and change in employment status requiring mark-to-market accounting treatment ($0.8 million); and
- an increase of $0.5 million in research and development outside services and $0.3 million in lab operations and travel costs.

We expect research and development expense to increase if our programs successfully advance. We do not believe that the historical costs are indicative of the future costs associated with these programs nor do they represent what any other future treatment program we initiate may cost. Due to the variability in the length of time and scope of activities necessary to develop a fertility treatment and uncertainties related to cost estimates and our ability to commercialize and/or obtain marketing approval for our treatments, accurate and meaningful estimates of the total costs required to bring our treatments to market are not available.

Because of the risks inherent in discovery and development, we cannot reasonably estimate or know:

- the nature, timing and estimated costs of the efforts necessary to complete the development of our programs;
- the anticipated completion dates of these programs; or
- the period in which material net cash inflows are expected to commence, if at all, from the programs described above and any potential future treatments.

### Selling, General and Administrative Expense

Selling, general and administrative costs consist of ongoing costs to run our daily operations and internal costs to support the international launch of ACE access program for the AUGMENT treatment. The $1.6 million or 47% increase in selling, general and administrative expense for the three months ended June 30, 2014 as compared to the three months ended June 30, 2013 was primarily due to:

- an increase of $0.7 million for employee compensation and related benefits, including stock-based compensation expense. The increase was primarily driven by the hiring of new selling, general and administrative personnel and stock-based compensation expense related to Founders’ shares requiring mark-to-market accounting treatment ($0.3 million);
- an increase of $0.7 million in ACE access program set-up costs; and
- an increase of $0.2 million in legal and facilities expenses.

The $2.1 million or 36% increase in selling, general and administrative expense for the six months ended June 30, 2014 as compared to the six months ended June 30, 2013 was primarily due to:

- an increase of $0.9 million for employee compensation and related benefits. The increase was primarily driven by the hiring of new selling, general and administrative personnel;
- an increase of $0.7 million in ACE access program set-up costs; and
- an increase of $0.5 million in legal and facilities expenses.

### Interest (Expense) / Income, net

Interest expense, net included $0.3 million of interest income offset by $0.3 million of short-term investment amortization and interest expense incurred to record the final installment payment due to Intrexon at fair value. In the three months ended June 30, 2013 there was immaterial interest income related to short-term investments resulting from the proceeds of our Series B Preferred Stock financing and our private placements of common stock.

Interest expense, net was $0.1 million for the six months ended June 30, 2014, and included $0.5 million of interest income offset by $0.6 million of short-term investment amortization and interest expense incurred to record the final installment payment due to Intrexon at fair value. In the six months ended June 30, 2013 there was immaterial interest income related to short-term investments resulting from the proceeds of our Series B Preferred Stock financing and our private placements of common stock.

### Loss from Equity Method Investment

Loss from equity method investment was $0.3 million and $0.4 million for the three and six months ended June 30, 2014, respectively. These losses result from our OvaXon joint venture established in December 2013.

### Liquidity and Capital Resources

### Sources of Liquidity

We have not generated any commercial sales to date. We have instead relied on the proceeds from sales of equity securities to fund our operations. Our short-term investments primarily trade in liquid markets, and the average days to maturity of our portfolio as of June 30, 2014 are less than six months. Because our fertility treatments are in various stages of development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our treatments or whether or when we may achieve profitability.

Our significant capital resources are as follows (in thousands):

|  | June 30, 2014 | December 31, 2013 |
| --- | ---: | ---: |
| Cash, cash equivalents and short-term investments | $81,368 | $44,427 |
| Working capital | 75,561 | 39,303 |

| Cash (used in) provided by: | Six Months Ended, June 30, 2014 | 2013 |
| --- | ---: | ---: |
| Operating activities | $(11,502) | $(9,220) |
| Investing activities | (41,635) | (10,017) |
| Capital expenditures (included in investing activities above) | (1,157) | (234) |
| Financing activities | 51,612 | 32,654 |

### Cash Flows

Cash used in operating activities in all of the periods presented was primarily attributed to the funding of our net loss. Cash flows from operations can vary significantly due to various factors, including changes in the net loss and the timing of disbursements made for accounts payable and accruals.

Cash used in investing activities for the six months ended June 30, 2014 included purchases of $57.6 million of short-term investments, proceeds from maturities of short-term investments of $14.3 million and $4.4 million in sales of short-term investments. Our investing activities for the six months ended June 30, 2014 included a $1.5 million investment in a joint venture. Capital expenditures in the six months ended June 30, 2014 primarily consisted of manufacturing equipment.

Cash used in investing activities for the six months ended June 30, 2013 included $10.8 million in purchases of short-term investments and proceeds of $1.0 million from maturities of short-term investments. Capital expenditures in the six months ended June 30, 2013 primarily consisted of laboratory equipment.

Net cash provided by financing activities for the six months ended June 30, 2014 was primarily the result of a registered offering of an aggregate of 5,518,630 shares of common stock at a price per share of $10.00 resulting in net proceeds of $51.6 million.

Net cash provided by financing activities for the six months ended June 30, 2013 was primarily the result of the private placement sale of an aggregate of 3,888,880 shares of common stock at a price per share of $9.00 resulting in net proceeds of $32.7 million.

We will need substantial additional funds to support our planned operations. In the absence of additional funding, business development activities, and treatment sales, we expect our existing cash, cash equivalents and marketable securities of $81.4 million at June 30, 2014 will enable us to fund our current operating plan into 2016. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our fertility treatments, and the extent to which we may enter into collaborations with third parties for development and commercialization of our treatments, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our current treatments.

Our future capital requirements will depend on many factors, including:

- continuing to provide the AUGMENT treatment in international IVF clinics in regions where we have launched the treatment, expanding the use of the treatment in those regions, and introducing our ACE access program into international IVF clinics in new international regions;
- educating physicians and embryologists on the use of the AUGMENT treatment;
- incurring the costs associated with expansion of foreign operations;
- establishing a domestic and international sales, marketing, manufacturing and distribution infrastructure to commercialize the AUGMENT treatment and any other potential fertility treatment that we successfully develop;
- conducting further studies of, continuing optimization of and ultimately commercially launching the OvaPrime treatment;
- receiving revenue, if any, from commercial activities involving the AUGMENT treatment, the OvaPrime treatment or any other potential fertility treatments;
- continuing research and preclinical development of the OvaTure treatment, both internally and in collaboration with Intrexon, and other potential fertility treatments;
- initiating any clinical trials of the OvaTure treatment and other potential fertility treatments;
- collaborating with Intrexon through the OvaXon joint venture to create new applications to prevent inherited diseases for human and animal health;
- following the regulatory process in the United States and abroad, including the premarketing and marketing approval requirements, to which some of our potential fertility treatments may be subject;
- following the regulatory or institutional review board review of our potential fertility treatments that are subject to such review;
- preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property- related claims;
- establishing collaborations and partnerships on favorable terms, if at all; and
- developing, acquiring or in-licensing other potential fertility treatments and technologies.

Until such time, if ever, that we can generate substantial treatment revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or treatments or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our fertility treatment development or future commercialization efforts or grant rights to develop and market treatments that we would otherwise prefer to develop and market ourselves.

### Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

### Contractual Obligations

There have been no material changes to our contractual obligations set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2013, except for commitments resulting from our public offering as follows:

In March 2014, pursuant to our Exclusive License Agreement with Massachusetts General Hospital, or MGH, our public offering triggered a $1.0 million license fee to be paid to MGH within one year. We paid half of this fee, or $0.5 million, to MGH in April 2014, and the remaining $0.5 million will become due in March 2015.

### Recently Adopted Accounting Standards

There are no recently issued accounting standards that have a material impact on us.

## Market risk

As filed, 1,010 characters.

Our interest income is sensitive to changes in the general level of U.S. interest rates, particularly since a significant portion of our investments are in money market funds and corporate obligations. We do not enter into investments for trading or speculative purposes. We maintain our cash, cash equivalents and short-term investments with a high quality, accredited financial institution. Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase.

A hypothetical 100 basis point increase in interest rates would result in an approximate $0.6 million decrease in the fair value of our investments as of June 30, 2014, as compared to an approximate $0.1 million decrease as of December 31, 2013. We have the ability to hold our fixed income investments until maturity and, therefore, we do not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.

## Controls and procedures

As filed, 1,936 characters.

*Evaluation of Disclosure Controls and Procedures.* Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2014. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2014, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

*Changes in Internal Controls.* No change in our internal control over financial reporting occurred during the fiscal quarter ended June 30, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,514 characters.

You should carefully review and consider the information regarding certain factors that could materially affect our business, financial condition or future results set forth under Item 1A. (Risk Factors) in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. There have been no material changes from the factors disclosed in our 2013 Annual Report on Form 10-K, although we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the Securities and Exchange Commission, including the additional risk factor set forth below.

***We and certain of our executive officers are currently subject to securities class action litigation in connection with our announcement of receiving an “untitled” letter from the FDA, that could result in substantial costs and divert management’s attention.***

Following our announcement of an “untitled” letter from the FDA, a purported shareholder class action was filed against us and certain of our executive officers alleging violation of federal securities laws. We believe such claims are without merit, and will engage in a vigorous defense of such litigation. In connection with such litigation, we could incur substantial costs and such costs and any related settlements or judgments may not be covered by insurance. We could also suffer a significant adverse impact on our reputation and divert management’s attention and resources, which could have a material adverse effect on our business.

Filed Aug 7, 2014.
Source: SEC EDGAR, the filing index for accession 0001104659-14-057930. Last ingested by Listed: Nov 15, 2026, 00:20 ET. No prices; not investment advice.
